Alaina Garbens

Alaina Garbens

Auto-generated profile, based on publicly available information

Alaina Garbens

Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
CWChristopher J D Wallis
Christopher J D Wallis
KLKirk Lo
Kirk Lo
YLYuna Lee
Yuna Lee
YKYonah Krakowsky
Yonah Krakowsky
AGAlaina Garbens
Alaina Garbens
RNRobert K Nam
Robert K Nam

1 December 2009 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
LHL.H. Higgins
L.H. Higgins
HWHenry G. Withers
Henry G. Withers
AGA. Garbens
A. Garbens
HLH.D. Love
H.D. Love
LMLeonardo Julian Magnoni
Leonardo Julian Magnoni
CMC.D. Moyes
C.D. Moyes

14 May 2015 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
MSMary K Samplaski
Mary K Samplaski
ADApostolos Dimitromanolakis
Apostolos Dimitromanolakis
KLKirk C Lo
Kirk C Lo
EGEthan D Grober
Ethan D Grober
BMBrendan Mullen
Brendan Mullen
KJKeith A Jarvi
Keith A Jarvi
In humans, sperm DNA fragmentation rates have been correlated with sperm viability rates. Reduced sperm viability is associated with high sperm DNA fragmentation, while conversely high sperm viability is associated with low rates of sperm DNA fragmentation. Both elevated DNA fragmentation rates and poor viability are correlated with impaired male fertility, with a DNA fragmentation rate of > 30% indicating subfertility. We postulated that in some men, the sperm viability assay could predict the sperm DNA fragmentation rates. This in turn could reduce the need for sperm DNA fragmentation assay testing, simplifying the infertility investigation and saving money for infertile couples. All men having semen analyses with both viability and DNA fragmentation testing were identified via a prospectively collected database. Viability was measured by eosin-nigrosin assay. DNA fragmentation was measured using the sperm chromosome structure assay. The relationship between DNA fragmentation and viability was assessed using Pearson’s correlation coefficient. From 2008-2013, 3049 semen analyses had both viability and DNA fragmentation testing. A strong inverse relationship was seen between sperm viability and DNA fragmentation rates, with r = -0.83. If viability was ≤ 50% (n = 301) then DNA fragmentation was ≥ 30% for 95% of the samples. If viability was ≥ 75% (n = 1736), then the DNA fragmentation was ≤ 30% for 95% of the patients. Sperm viability correlates strongly with DNA fragmentation rates. In men with high levels of sperm viability ≥ 75%, or low levels of sperm viability ≤ 30%, DFI testing may be not be routinely necessary. Given that DNA fragmentation testing is substantially more expensive than vitality testing, this may represent a valuable cost-saving measure for couples undergoing a fertility evaluation.

15 March 2016 in The Prostate
Verified
Journal Article
Closed access
PDF file
RNRobert K. Nam
Robert K. Nam
TBTania Benatar
Tania Benatar
CWChristopher J. D. Wallis
Christopher J. D. Wallis
YAYutaka Amemiya
Yutaka Amemiya
WYWenyi Yang
Wenyi Yang
ASArun Seth
Arun Seth

29 January 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
OTOlivier Trédan
Olivier Trédan
AGAlaina B. Garbens
Alaina B. Garbens
ALAlshad S. Lalani
Alshad S. Lalani
ITIan F. Tannock
Ian F. Tannock
Hypoxic tumor cells are likely to be resistant to conventional chemotherapy, in large part because many anticancer drugs are unable to penetrate into poorly oxygenated tumor tissue. Here, we used quantitative immunofluorescence to study the distribution of mitoxantrone and AQ4N in tumor tissue. AQ4N is a prodrug activated under hypoxic conditions to AQ4, which is structurally similar to mitoxantrone and inhibits topoisomerase II. We characterized the penetration of mitoxantrone and AQ4N/AQ4 through multilayered cell cultures (MCC) and in relation to blood vessels and hypoxic regions in human tumor xenografts. We also studied tumor growth delay after treatment with each agent alone and with the combination. In both MCC and xenografts, mitoxantrone is taken up by proximal cells and penetrates slowly to distant regions. In contrast, AQ4N rapidly penetrates MCC and tumor tissue in vivo, and AQ4N (or its reduced form AQ4) is detected at high concentration within hypoxic regions. The targeting of mitoxantrone to oxygenated regions and AQ4N/AQ4 to hypoxic tumor regions results in effective drug exposure over the entire tumor after combined treatment and increases tumor growth delay compared with either drug alone. The combination of a clinically used anticancer drug with limited tissue penetration and a structurally related drug activated in regions of tumor hypoxia is an effective strategy to overcome chemoresistance due to the tumor microenvironment. This study supports clinical evaluation of AQ4N in combination with conventional anticancer agents, such as mitoxantrone. [Cancer Res 2009;69(3):940–7]

1 January 2017 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
Mitchell GoldenbergMitchell Goldenberg
Mitchell Goldenberg
AGA. Garbens
A. Garbens
PSP. Szasz
P. Szasz
THT. Hauer
T. Hauer
TGT. P. Grantcharov
T. P. Grantcharov